ReviewOphthalmology2025
Instrument-Based Screening for the Detection of Amblyopia and Amblyopia Risk Factors: A Report by the American Academy of Ophthalmology.
Review in Ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Diagnostic Accuracy of a Retinal Birefringence Scanning Device Compared With a Traditional Autorefraction Device.JAMA ophthalmology · 2026Trial
- Binocular Vision Anomalies: An Update on Prevalence, Impact, Technological and Treatment Developments and Current Challenges.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Review
- Keeping myopia away: The importance of maintaining hyperopic reserve in premyopia.Taiwan journal of ophthalmologyReview
Corrections and comments
- Erratum issuedCorrigendum.2026
Authors and funding
8 authors.
Funding
Abstract
purposeTo review the published literature on the diagnostic accuracy of instrument-based screening devices used to detect amblyopia and amblyopia risk factors (ARFs).
methodsA literature search of the PubMed database with no date restrictions and limited to articles published in English was last conducted in January 2025. The search yielded 291 articles; 41 were reviewed in full text, and 33 met the criteria for inclusion in this assessment. The panel methodologist assigned a level of evidence rating to each of the included studies.
resultsAll 33 articles (which reported results from 28 072 children) were rated level III. Nine screening devices were discussed in the included studies; the most common were the Plusoptix, Spot, and Retinomax. Results from 28 072 children were reported, and most studies focused on children aged 6 years and younger. The most common study setting was ophthalmology clinics, followed by school-based settings and then community-based settings. For detecting ARFs, sensitivity ranged from 32.3% to 100% and specificity ranged from 38.7% to 94% (Plusoptix sensitivity 32.3%-100%, specificity 38.7%-100%; Retinomax sensitivity 70%-95%, specificity 58%-94%; Spot sensitivity 60%-94%, specificity 67%-97%). Examination failure thresholds varied, but most studies after 2013 followed the 2013 American Association for Pediatric Ophthalmology and Strabismus (AAPOS) guidelines. For the 21 studies that reported the referral rate (percentage of children who failed based on the screening result), the rate varied significantly (2.26%-63%). Higher referral rates were seen in studies based in ophthalmology clinics.
conclusionsThe best available evidence supports the use of instrument-based screening devices to detect amblyopia and ARFs, although there were high levels of variability in the study design, setting, and target age for screening. Additionally, diagnostic accuracy varied on the basis of the screening device used. Future studies of instrument-based screening devices would benefit from following standardized reporting measures for diagnostic accuracy, which will strengthen the evidence base and provide more complete data on which to base decisions about the most appropriate screening programs and strategies. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.